These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7589597)

  • 21. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
    Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
    Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.
    Abdel-Nabi H; Doerr RJ; Lamonica DM; Cronin VR; Galantowicz PJ; Carbone GM; Spaulding MB
    Radiology; 1998 Mar; 206(3):755-60. PubMed ID: 9494497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does positron emission tomography/computed tomography change management in colorectal cancer?
    Falconer R; Connor S; Balasingam A; Eglinton T
    ANZ J Surg; 2018 Apr; 88(4):E248-E251. PubMed ID: 27788564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of FDG PET/CT in patients with colorectal cancer metastases.
    Kochhar R; Liong S; Manoharan P
    Cancer Biomark; 2010; 7(4):235-48. PubMed ID: 21576816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
    Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
    Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.
    Sanli Y; Kuyumcu S; Ozkan ZG; Kilic L; Balik E; Turkmen C; Has D; Isik G; Asoglu O; Kapran Y; Adalet I
    Ann Nucl Med; 2012 Aug; 26(7):551-8. PubMed ID: 22644560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of (18)F-FDG dual-head gamma-camera coincidence imaging in recurrent or metastatic colorectal carcinoma.
    Even-Sapir E; Lerman H; Figer A; Rabau M; Livshitz G; Inbar M; Gutman M
    J Nucl Med; 2002 May; 43(5):603-9. PubMed ID: 11994521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDG PET and PET/CT for colorectal cancer.
    Delbeke D; Martin WH
    Methods Mol Biol; 2011; 727():77-103. PubMed ID: 21331930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
    Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
    Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making.
    Kantorová I; Lipská L; Bêlohlávek O; Visokai V; Trubaĉ M; Schneiderová M
    J Nucl Med; 2003 Nov; 44(11):1784-8. PubMed ID: 14602860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?
    Selzner M; Hany TF; Wildbrett P; McCormack L; Kadry Z; Clavien PA
    Ann Surg; 2004 Dec; 240(6):1027-34; discussion 1035-6. PubMed ID: 15570208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
    Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
    Hildebrandt MG; Gerke O; Baun C; Falch K; Hansen JA; Farahani ZA; Petersen H; Larsen LB; Duvnjak S; Buskevica I; Bektas S; Søe K; Jylling AM; Ewertz M; Alavi A; Høilund-Carlsen PF
    J Clin Oncol; 2016 Jun; 34(16):1889-97. PubMed ID: 27001573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incremental value of CT in PET/CT of patients with colorectal carcinoma.
    Kamel IR; Cohade C; Neyman E; Fishman EK; Wahl RL
    Abdom Imaging; 2004; 29(6):663-8. PubMed ID: 15162236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
    Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
    Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of 18-fluorodeoxyglucose positron emission/computed tomography in the management of recurrent colorectal cancer.
    Liong SY; Kochhar R; Renehan AG; Manoharan P
    ANZ J Surg; 2012 Oct; 82(10):729-36. PubMed ID: 22989147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy.
    Eubank WB; Mankoff DA; Schmiedl UP; Winter TC; Fisher ER; Olshen AB; Graham MM; Eary JF
    AJR Am J Roentgenol; 1998 Oct; 171(4):1103-10. PubMed ID: 9763005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic Value of (18)F-FDG PET/CT in Detecting Local Recurrent Colorectal Cancer: A Pooled Analysis of 26 Individual Studies.
    Yu T; Meng N; Chi D; Zhao Y; Wang K; Luo Y
    Cell Biochem Biophys; 2015 Jun; 72(2):443-51. PubMed ID: 25737131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.